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Jill A. Livengood, Ph.D. 
Combining DOE with an empirical approach to improve 
vaccine formulation development 
Vaccines 
1. One of the 10 greatest Public Health 
Achievements of the 20th Century 
(MMWR 1999) 
2. Antigen or attenuated live virus to 
trigger immune response for disease 
protection 
3. Biological Products 
– Stability is critical 
4. Pediatric and Adult 
– Complex immunological environment 
– Healthy subjects 
 
Data from CDC, graph by Leon Farrant 
   










Quality by Design 
Begin vaccine formulation with the end in mind 
QbD: “a systematic approach to development that begins with predefined objectives 
and emphasizes product and process understanding and process control, based on 
sound science and quality risk management in order to ensure the quality of the 
product” - ICH Q8  
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Ph I   Preclinical Ph III Reg. Ph II 
QTPP (CQA) 
Potential 
CQA  list 
Update CQAs and set 
ranges based on 
nonclinical/ clinical 
results, analytical data 
Final CQA;  




QTPP for Live Attenuated Vaccines (example) 
1. Potency (live biological product)  
– Initial retention of titer: < 0.5 log10 loss of titer 
– Shelf life ~ 2 years at 4°C 
• lyophilized 
– Stability at 4º, 25º and 40ºC storage: < 0.5 log10 loss of titer 
– Freeze-thaw liquid stability: < 0.5 log loss of titer 
– Stable in liquid state during processing 
2. Physical Attributes 
– Re-constitution time: < 2 minutes to a clear, colorless solution 
– pH: physiologic (7.2 to 7.4) 
– isotonicity: 280 to 390 mOsm/L 
– Cake appearance: white, dense, uniform cake, no evidence of collapse 
3. Animal-derived protein-free formulation 
 
 
Begin (formulation development) with the end in mind 
Part I: Formulation Development – 
Empirical Approach 
1. Product Biology 
2. Literature search 
3. Freedom to Operate 
4. Analytics 
– Stability indicating 
assay 
– High throughput 
5. Buffer Screen: liquid 
Excipient Identification and Screening 















Pluronic® block copolymers (0.0001-1.0%) 
Polysorbate 80 (0.05%) 
Amino acids 




Osmolytes Urea (0.2 to 0.5%) 
Salts Magnesium chloride, Sodium chloride (50 to 150mM) 




Buffer Screen / Liquid Stability / Lyo feasibility 
 Empirical approach 
Buffer Choice (Liquid) Liquid Buffer Screen Sugar plus excipient pre/post lyo 
Sugar plus excipient: Stability at 25°C for 2 
weeks 
Histidine Histidine,  Trehalose Trehalose/HSA Sucrose/HSA 
HEPES HEPES,  Trehalose Trehalose/Lactose Sucrose/Lactose 
Tris Tris,  Trehalose Trehalose/Sucrose Sucrose/MSG 
PBS PBS, Trehalose Trehalose/Sorbitol Sucrose/Alanine 
Citrate PBS,  Trehalose Trehalose/Mannitol Sucrose/Methionine 






















Vaccine drug substance buffer exchanged, lyophilized and 
subjected to accelerated and real time stability 
 
1. disaccharide/ protein complex/organic buffer/inorganic salt 
2. disaccharide/ protein complex/monosaccharide 
3. disaccharide/amino acid 
4. disaccharide/ amino acid 
5. disaccharide/ amino acid/inorganic salt 
6. disaccharide/ monosaccharide/amino acid 
7. disaccharide /protein complex/ inorganic buffer/ inorganic salts 






Feasibility of Lyophilized Formulations 
Empirical approach 











Freeze-Thaw of Liquid Formulations 
Liquid 









1 2 3 4 5 6 7 8 
TCID50/mL 
Formulation 
Loss upon lyophilization 
Liquid 
Week 0 
RX Liquid Lyophilized 
1 5.79E+05 2.40E+05 
2 2.30E+05 4.04E+05 
3 8.09E+04 5.00E+04 
4 7.57E+04 6.48E+04 
5 8.92E+03 1.46E+04 
6 1.49E+05 1.40E+05 
7 1.78E+05 1.41E+05 
8 7.64E+03 1.11E+04 
Target Titer = 2E5 
TCID50/mL 
Liquid and Post-Lyophilization Titers 
Potency CQA 
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 1    2        3            4  
  
5       6                   7                 8 
Cake appearance after Lyophilization  
Physical Attributes CQA 
12 
Physical Product Characteristics  













 I 72 7.15 3 
Shrinking on 
sides and 
bottom   352 1.79 
II 17 6.87 5 Whole  283 0.77 
III 15 7.55 3 Cracked  292 1.04 
IV 14 7.50 1 Powder  311 2.21 
V 24 7.15 1 Small Spheres  386 3.21 
VI 23 7.52 4 
Melting on 
bottom  310 0.47 
VII 29 7.01 5 Whole  273 1.15 
VIII 29 7.33 4 
Shrinking on 





Rx1 Rx2 Rx3 Rx4 Rx5 Rx6 Rx7 Rx8 
4C, 26W 0.18 -0.56 -1.53 -1.20 -1.71 -0.37 -0.61 -1.94 
25C, 12W -0.22 -1.58 -2.40 -3.14 -5.30 -1.13 -1.11 -2.52 



























Log loss from Target titer: 5.3 log10 
15 
Estimated Shelf Life – 4°C 


































  Study 1 Log10 Titer   
 Formulation   Week 0 Expiry  ESL (Weeks) 
 Formulation I 5.37 4.37 >52 
 Formulation II 5.50 4.50 18 
 Formulation III 4.69 3.69 21 
 Formulation IV 4.80 3.80 22 
 Formulation V 4.16 3.16 36 
 Formulation VI 5.14 4.14 >52 
 Formulation 
VII  5.14 4.14 46 
 Formulation 
VIII 4.05 3.05 26 
16 
Select Best Formulation based on QTPP 
Study 1: empirical approach 
Rx Reconstitution 
time 







1 X X X X 
2 X X X 
3 X X X 
4 X X 
5 X 
6 X X X x x 
7 X X X 
8 x x x 
Part II: Formulation Development - 
DOE 
Ph I   Preclinical Ph III Registr. Ph II 
QTPP (CQA) 
18 
• Study 1 identified formulation 6 as a potential formulation 
• DOE designed based on: 
o Buffer: fixed, pH 7.2 
o Excipient 1: 10 to 40 mg/mL 
o Excipient  2: 5 to 20 mg/mL 
o Excipient  3: 20 to 50 mg/mL 
• Definitive screen designed 16 formulations within the defined ranges  
o Formulations determined using JMP’s DOE functionality 
• New formulations manufactured and lyophilized  
• Samples placed on stability at 4, 25 and 40°C 
o 4°C: 0, 0.5, 1, 2, 3, 6, 12, 18 and 24 months 
o 25°C: 0, 0.5, 1, 2, 3 and 6 months 
o 40°C: 0, 2, 4 and 6 weeks  
 
 
Design of Experiments (DOE) 















































































• Week 0-Lyo   
o Whole cakes with some 
shrinkage 
• 4⁰C and 25⁰C  stability 
o No change through week 12 
• 40⁰C stability 
o Week 2: Collapse of 11 of 17 
formulations 
o Week 4: 12 of 17 
formulations 










 Physical Characteristics CQA  
Week 0-Lyo 
40⁰C 





 1 0.71 
 2 0.5 
 3 0.46 
 4 1.01 
 5 0.45 
 6 0.74 
7 1.06 
 8 0.72 
 9 0.98 
 10 1.08 
11 0.87 
12 0.98 
 13 1.46 
 14 0.6 
15 1.21 
16 0.77 




Rx1 Rx2 Rx3 Rx4 Rx5 Rx6 Rx7 Rx8 Rx9 Rx10 Rx11 Rx12 Rx13 Rx14 Rx15 Rx16 Rx17 
4C, 26 W -1.36 -1.23 -1.06 -1.24 -1.26 -1.11 -1.20 -0.92 -1.00 -1.07 -2.00 -1.53 -1.30 -1.24 -1.06 -1.19 -0.17 
25C, 26 W -1.73 -1.97 -1.45 -2.35 -2.46 -1.88 -1.97 -1.86 -1.75 -1.84 -2.96 -2.56 -2.45 -2.65 -1.72 -1.76 -1.02 

























Potency Loss from Target Titer 
22 
Statistical analysis of DOE: Most desirable formulations 
predicted 
 
Excipient 1       Excipient 2         Excipient 3        Desirability 
|  23 
Design space with lead excipients 
24 
Study 2 down-selection 
Rx  
Reconstitution 
time/moisture  LIQ F/T  
Cake 




1 x x x x 
2 x x x 
3 x x x x 
4 x x x x 
5 x x x x 
6 x x x x 
7 x x x 
8 x x x x 
9 x x x x 
10 x x x x 
11 x x x x 
12 x x x x 
13 x x x x 
14 x x x 
15 x x x x 
16 x x x x x 
17 x x x x 
Part III: DOE Response Curve / 
Central Composite Design 
Ph I   Preclinical Ph III Registr. Ph II 
QTPP (CQA&ATP) 
Study 3: DOE  
central composite design with 2 center points  
| 26 
 
Rx Excipient 1 Excipient 2 
  mg/mL mg/mL 
1 50.00 70.00 
2 40.00 50.00 
3 40.00 50.00 
4 25.86 50.00 
5 30.00 70.00 
6 54.14 50.00 
7 50.00 30.00 
8 40.00 78.28 
9 30.00 30.00 
10 40.00 21.72 















Stability Study 3 
Potency CQA 
27 
1 2 3 4 5 6 7 8 9 10 
Liquid -0.27 -0.28 -0.26 -0.13 -0.22 -0.48 -0.35 -0.23 -0.22 -0.36 
Week 0 -0.63 -0.48 -0.66 -0.45 -0.27 -0.38 -0.68 -0.29 -0.46 -0.45 
25C Week 2 -0.39 -0.93 -0.78 -0.62 -0.68 -0.85 -1.18 -0.86 -1.05 -0.50 
25C Week 4 -0.98 -0.89 -1.44 -0.71 -0.76 -0.94 -1.43 -1.32 -1.01 -0.91 
40C Week 2 -1.59 -1.34 -1.63 -1.54 -1.30 -1.95 -1.82 -1.48 -1.88 -2.28 























Potency Loss from Target Titer 
Cake Appearance Study 3 
 Physical Characteristics CQA  
RX 1* 4* 9** 2*** 6*** 
Week 0  
 
40°C Week 2 
25°C Week 4 
28 




2. Physical Characteristics 
– Cake structure 
– Osmolality 
 
3. Choose 3 formulations to move to next stage 
 
Down selection – based on TPP 
Part IV: Lyophilization Cycle Design 
Process Engineering 
Ph I   Preclinical Ph III Registr. Ph II 
QTPP (CQA) 
Process Engineering of Lyophilization Cycle 
• Thermal Properties Characterization of Candidate Formulations  
– Freeze Drying Microscopy, Differential Scanning Calorimetry & Electrical 
Resistance 
 
• Cycle design and engineering 
– Determine Lyophilization Critical Process Parameters (CPPs) 
• Shelf temp 
• Chamber pressure 
• Cycle duration  
– Refine parameters 
• Thermal treatment? 
• Produce range of residual moistures  
– Confirm target CPP and CQA  
• At large scale 
• Stability Studies 
• On range of residual moistures 
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Estimated Shelf Life (90% Confidence): >176 Weeks 
QTPPs for Live Attenuated Vaccines (example) 
1. Potency (live biological product)  
– Initial retention of titer: < 0.5 log10 loss of titer 
– Shelf life ~ 2 years at 4°C 
• lyophilized 
– Stability at 4º, 25º and 40ºC storage: < 0.5 log10 loss of titer 
– Freeze-thaw liquid stability: < 0.5 log loss of titer 
– Stable in liquid state during processing 
2. Physical Attributes 
– Re-constitution time: < 2 minutes to a clear, colorless solution 
– pH: physiologic (7.2 to 7.4) 
– isotonicity: 280 to 390 mOsm/L 
– Cake appearance: white, dense, uniform cake, no evidence of collapse 
3. Animal-derived protein-free formulation 
 
 
Begin (formulation development) with the end in mind 
34 
Combining empirical approach with DOE enables: 
– Shorter development time 
– Better understanding of design space 
– Understanding of excipient interactions 
– Evaluate more factors in analysis 
– Use statistical approach to justify excipient choices and ranges 
–  Apply to TPP 
 
– Compare and contrast purely empirical with combined empirical /DOE 
Take home message  
Ph I   Preclinical Ph III Registr. Ph II 
QTPP (CQA) 
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